Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
different doses of oridonin, and cell proliferation and migration were detected using CCK8, EdU, Transwell, and wound healing assays
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In conclusion, the data indicate that oridonin suppresses LC malignant progression by targeting S100A11.
[BACKGROUND] Lung cancer (LC) is the second most lethal cancer and efficient treatments are missing.
APA
Luo Y, Li J, et al. (2026). Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11.. Current medicinal chemistry, 33(2), 315-328. https://doi.org/10.2174/0109298673352893241228015939
MLA
Luo Y, et al.. "Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11.." Current medicinal chemistry, vol. 33, no. 2, 2026, pp. 315-328.
PMID
39851114 ↗
Abstract 한글 요약
[BACKGROUND] Lung cancer (LC) is the second most lethal cancer and efficient treatments are missing. Our understanding of the underlying pathogenic mechanisms remains limited. Oridonin is a compound extracted from the Chinese herb Rabdosia rubescens with anticancer properties. Nevertheless, its effects on LC and the underlying mechanisms remain unknown.
[METHODS] In the current research, A549 and Hcc1833 cells were treated with different doses of oridonin, and cell proliferation and migration were detected using CCK8, EdU, Transwell, and wound healing assays. A subcutaneous tumor and caudal vein metastasis model was generated to verify the inhibitory effects of oridonin on Hcc1833 tumor growth and metastasis in vivo. Proteomics analyses then were performed to examine the regulatory mechanism. LiP-SMap combined with microscale thermophoresis and molecular docking analyses were used to validate the relationship between oridonin and S100A11.
[RESULTS] Data showed that oridonin suppressed cell proliferation and migration depending on dose and suppressed tumor growth and invasion. LiP-SMap and molecular docking analyses confirmed that oridonin interacted with the Asn-53 residue of S100A11, which inhibited the activation of oridonin. S100A11 overexpression reversed the inhibitory effects of oridonin on cell proliferation and migration.
[CONCLUSION] In conclusion, the data indicate that oridonin suppresses LC malignant progression by targeting S100A11.
[METHODS] In the current research, A549 and Hcc1833 cells were treated with different doses of oridonin, and cell proliferation and migration were detected using CCK8, EdU, Transwell, and wound healing assays. A subcutaneous tumor and caudal vein metastasis model was generated to verify the inhibitory effects of oridonin on Hcc1833 tumor growth and metastasis in vivo. Proteomics analyses then were performed to examine the regulatory mechanism. LiP-SMap combined with microscale thermophoresis and molecular docking analyses were used to validate the relationship between oridonin and S100A11.
[RESULTS] Data showed that oridonin suppressed cell proliferation and migration depending on dose and suppressed tumor growth and invasion. LiP-SMap and molecular docking analyses confirmed that oridonin interacted with the Asn-53 residue of S100A11, which inhibited the activation of oridonin. S100A11 overexpression reversed the inhibitory effects of oridonin on cell proliferation and migration.
[CONCLUSION] In conclusion, the data indicate that oridonin suppresses LC malignant progression by targeting S100A11.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Diterpenes
- Kaurane
- Humans
- Lung Neoplasms
- Cell Proliferation
- Molecular Docking Simulation
- Cell Movement
- Animals
- Mice
- Drug Screening Assays
- Antitumor
- Cell Line
- Tumor
- Disease Progression
- Structure-Activity Relationship
- Antineoplastic Agents
- Inbred BALB C
- Phytogenic
- Dose-Response Relationship
- Drug
- Oridoninm
- S100A11
- lung cancer
- malignant progression
… 외 2개
같은 제1저자의 인용 많은 논문 (5)
- Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial.
- Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy.
- Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy-Induced Cardiac Fibrosis Based on Single-Cell Transcriptomic Analysis.
- Commentary: Acceptance and commitment therapy combined with usual care improves psychosocial outcomes and reduces complications in patients with permanent colostomies after colorectal cancer surgery: a retrospective cohort study.
- A novel triple-modality approach overcoming prohibitive hepatopulmonary shunt (HPS): Enabling yttrium-90 selective internal radiation therapy (Y90-SIRT) and subsequent curative resection in massive hepatocellular carcinoma (HCC).
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.